Navegando por Palavras-chave "laser-induced thermal therapy"

Agora exibindo 1 - 2 de 2
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Intratumor Cisplatin Nephrotoxicity in Combined Laser-Induced Thermal Therapy for Cancer Treatment
    (Wiley, 2017) Palumbo, Marcel N. [UNIFESP]; Cervantes, Onivaldo [UNIFESP]; Eugenio, Cecilia [UNIFESP]; Hortense, Flavia T. P. [UNIFESP]; Ribeiro, Joao C. [UNIFESP]; Paolini, Ana Amelia P.; Tedesco, Antonio C.; Sercarz, Joel A.; Paiva, Marcos B. [UNIFESP]
    Introduction: Thermal ablation of tumors by Nd:YAG laser has been growing as a multidisciplinary subspecialty defined as laser-induced thermal therapy (LITT), and has been increasingly accepted as a minimally invasive method for palliation of advanced or recurrent cancer. Previous studies have shown that adjuvant chemotherapy can potentiate laser thermal ablation of tumors leading to improved palliation in advanced cancer patients. Objective: Evaluate nephrotoxicity by early markers of renal function in treating head and neck cancer using intra-tumor injections of cisplatin combined with laser-induced thermal therapy CDDP-LITT). Methods: Nine patients with recurrent head and neck tumors were treated by CDDP-LITT in order to determine nephrotoxicity related to this synergistic association. Among the tests requested to detect early were creatinine, magnesium, creatinine clearance, serum urea-BUN, type I urine, and proteinuria at 24 hours. Results: Twelve recurrent tumors in nine patients were treated by CDDP-LITT. Pain was the major complaint four patients), while other symptoms included dysphagia, dyspnea, bleeding, and difficulties in chewing. Fifteen laser procedures were performed and maximal CDDP dose was 50mg. None of the markers for nephrotoxicity showed changes at these levels of CDDP intra-tumor injections. Conclusion: This initial experience with (CDDP-LITT) indicates both safety and therapeutic potential for palliation of advanced head and neck cancer. However, safety and feasibility must be confirmed by longer follow up and further escalation of CDDP doses in a Phase I study to determine maximum tolerated dose (MTD) and demonstrate tangible benefits for patients. (C) 2017 Wiley Periodicals, Inc.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Update on Laser Photochemotherapy: An Alternative for Cancer Treatment
    (Bentham Science Publ Ltd, 2011-10-01) Paiva, Marcos Bandiera [UNIFESP]; Joo, Jayne; Abrahão, Márcio [UNIFESP]; Ribeiro, Joao Carlos [UNIFESP]; Cervantes, Onivaldo [UNIFESP]; Sercarz, Joel A.; Univ Calif Los Angeles; Universidade Federal de São Paulo (UNIFESP); Univ Calif Davis
    Although major progress has been made in surgery, radiation, and chemotherapy for the treatment of malignancy during the last 20 years, there has been little improvement in the survival of patients with recurrent or advanced head and neck cancer. Because of the ease and accessibility for surgery and their loco-regional biological behavior, head and neck cancers serve as an ideal model to test combined laser energy delivered via interstitial fiberoptics and chemotherapeutic agents activated by photo-thermal energy as an alternative, less invasive treatment for cancer. A number of investigators have shown that anthracyclines and cisplatin are likely candidates for light or heat activation in cancer cells. Maximum tolerated dose followed by photochemical and thermal activation via laser fiberoptics can improve treatment by sensitizing tumor response. The higher intratumor drug levels compared to systemic drug administration along with laser activation should also reduce systemic toxicity. In this article the authors analyze the concept of combining anti-cancer drugs and laser therapy and review the clinical application. In summary, the literature available suggests photochemotherapy with currently approved drugs and lasers may soon become an attractive alternative for cancer treatment.